Marshall Fordyce, Vera CEO
Gene therapy player turned kidney specialist Vera drops a dud in leadup to Nasdaq, pricing well below range
Vera Therapeutics took a big risk at the start of the year, pivoting away from its gene editing mission statement to chase a lead kidney …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
